Skip to content

Enovis ENOV Change in fair value of contingent consideration

Change in fair value of contingent consideration at other companies

Artivion logo
ArtivionAORT
$1.74M+161%
Globus Medical logo
Globus MedicalGMED
$6.35M+3,704%
CONMED logo
CONMEDCNMD
$722K-81.8%
Merit Medical Systems logo
Merit Medical SystemsMMSI
-$179K-117%
IAR
Integra LifeSciencesIART
-$1.29M-698%

Other financials

Income statement

See full
Revenue$589.2M+5.4%
Gross profit$365.5M+10.0%
Operating income$6.5M+114%
Net income-$8.8M+84.3%
EPS (diluted)-$0.15+84.7%

Balance sheet

See full
Cash & equivalents$33.1M-13.9%
Total debt$1.4B-3.1%
Total equity$1.5B-43.6%
Total assets$3.8B-21.4%

Cash flow

See full
Operating cash flow$24.0M+1,601%
CapEx$52.8M+22.1%
Free cash flow-$28.9M+35.7%

Valuation

See full
Market cap$1.23B-28.4%
Enterprise value$2.55B-17.1%
P/S0.5×-0.3×

Profitability

See full
Gross margin60.5%+4.0pp
Operating margin-47%+18.6pp
Net margin-49.9%+24.1pp
FCF margin-3.1%-1.1pp

Returns & leverage

See full
Return on equity-55.5%-1,722pp
Debt / equity0.9×+0.4×
Current ratio-0.5×

Where this comes from

Reported directly by Enovis in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: Enovis’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Enovis's change in fair value of contingent consideration.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Enovis's change in fair value of contingent consideration?
Enovis (ENOV) reported change in fair value of contingent consideration of $0 in Q1 2026.
How has Enovis's change in fair value of contingent consideration changed year-over-year?
Enovis's change in fair value of contingent consideration decreased by 100.0% year-over-year, from $1.79M to $0.
What does change in fair value of contingent consideration mean?
This reflects the non-cash adjustment to the fair value of earn-outs or contingent payments promised to sellers in previous business acquisitions. Fluctuations in this value indicate changes in the estimated probability or magnitude of meeting performance-based payout targets. It is a key indicator of how actual post-acquisition performance compares to initial management projections.